Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

双盲 认知 生活质量(医疗保健) 物理疗法 临床心理学
作者
Rachelle S. Doody,Gavrilova Si,Mary Sano,Ronald G. Thomas,Paul S. Aisen,Sergey O. Bachurin,Lynn Seely,David T. Hung
出处
期刊:The Lancet [Elsevier BV]
卷期号:372 (9634): 207-215 被引量:417
标识
DOI:10.1016/s0140-6736(08)61074-0
摘要

Summary Background Although treatments for Alzheimer's disease sometimes improve cognition, functional ability, or behaviour compared with baseline levels, such improvements are inconsistent across studies and measures, and effects diminish over time. More effective treatments are needed. We assessed the safety, tolerability, and efficacy of dimebon in the treatment of patients with mild-to-moderate Alzheimer's disease. Methods We enrolled 183 patients with mild-to-moderate Alzheimer's disease (mini-mental state examination [MMSE] scores 10–24) at 11 sites in Russia. Patients were randomly assigned by a computer-generated randomisation scheme to receive oral dimebon, 20 mg three times a day (60 mg/day [n=89]), or matched placebo (n=94). Other antidementia drugs were not allowed. The primary outcome measure assessed cognition, the difference in mean change from baseline to week 26, or last completed observation on the cognitive subscale of the Alzheimer's disease assessment scale (ADAS-cog). All patients and study personnel were blinded throughout the study. We compared dimebon with placebo with an intention-to-treat analysis, with last observation carried forward (ITT-LOCF) imputation. Analyses were repeated on the fully evaluable population, defined as all patients in the intention-to-treat population who had an ADAS-cog at week 26 and at least 80% compliance. 134 patients (68 in dimebon group, 66 in placebo group) enrolled in the 6-month blinded extension phase of the study. This trial is registered with Clinicaltrials.gov, number NCT00377715. Findings 155 (85%) patients completed the trial (78 [88%] in dimebon group, 77 [82%] in placebo group). Treatment with dimebon resulted in significant benefits in ADAS-cog compared with placebo (ITT-LOCF) at week 26 (mean drug-placebo difference −4·0 [95% CI −5·73 to −2·28]; p Interpretation Dimebon was safe, well tolerated, and significantly improved the clinical course of patients with mild-to-moderate Alzheimer's disease. Funding Medivation (USA).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
coolkid完成签到 ,获得积分0
刚刚
你怎么那么美完成签到,获得积分10
刚刚
游艺完成签到 ,获得积分10
3秒前
冬月完成签到 ,获得积分10
3秒前
薛乎虚完成签到 ,获得积分10
4秒前
5秒前
大胖完成签到,获得积分10
5秒前
野火197完成签到,获得积分10
9秒前
10秒前
量子星尘发布了新的文献求助10
13秒前
April完成签到,获得积分10
13秒前
周舟完成签到 ,获得积分10
16秒前
V_I_G完成签到 ,获得积分10
17秒前
nick完成签到,获得积分10
18秒前
高高高完成签到 ,获得积分10
21秒前
彪壮的亦瑶完成签到 ,获得积分10
22秒前
科研通AI2S应助科研通管家采纳,获得10
24秒前
Perry应助科研通管家采纳,获得60
24秒前
Akim应助科研通管家采纳,获得10
24秒前
鱼雷完成签到,获得积分10
25秒前
廿伊发布了新的文献求助10
27秒前
我是125完成签到,获得积分10
29秒前
依人如梦完成签到 ,获得积分10
30秒前
31秒前
PDIF-CN2完成签到,获得积分10
35秒前
雪雪完成签到 ,获得积分10
36秒前
37秒前
Willow完成签到,获得积分10
40秒前
研研研完成签到,获得积分10
41秒前
大橙子发布了新的文献求助10
43秒前
dejiangcj完成签到 ,获得积分10
44秒前
无味完成签到,获得积分10
45秒前
大气的尔蓝完成签到,获得积分10
46秒前
科研通AI5应助普鲁卡因采纳,获得10
47秒前
略略略完成签到 ,获得积分10
49秒前
zqlxueli完成签到 ,获得积分10
53秒前
无语的断缘完成签到,获得积分10
55秒前
hdx完成签到 ,获得积分10
56秒前
健壮的涑完成签到 ,获得积分10
57秒前
量子星尘发布了新的文献求助10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022